Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.71 USD
Change Today -0.54 / -3.54%
Volume 47.1K
DPRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

dipexium pharmaceuticals inc (DPRX) Snapshot

Open
$15.00
Previous Close
$15.25
Day High
$15.11
Day Low
$14.26
52 Week High
07/21/15 - $17.10
52 Week Low
09/3/14 - $9.16
Market Cap
151.5M
Average Volume 10 Days
33.9K
EPS TTM
$-1.79
Shares Outstanding
10.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIPEXIUM PHARMACEUTICALS INC (DPRX)

Related News

No related news articles were found.

dipexium pharmaceuticals inc (DPRX) Related Businessweek News

No Related Businessweek News Found

dipexium pharmaceuticals inc (DPRX) Details

Dipexium Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibiotics for the treatment of infectious diseases. It develops Locilex (pexiganan cream 0.8%), a novel, broad spectrum, and topical antibiotic, which is in phase 3 clinical trials for the treatment of mild infections of diabetic foot ulcers. The company was founded in 2010 and is based in New York, New York.

5 Employees
Last Reported Date: 03/23/15
Founded in 2010

dipexium pharmaceuticals inc (DPRX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $464.2K
Co-Founder and Executive Chairman
Total Annual Compensation: $364.2K
Vice President of Finance and Corporate Devel...
Total Annual Compensation: $248.8K
Chief Accounting Officer and Treasurer
Total Annual Compensation: $138.8K
Compensation as of Fiscal Year 2014.

dipexium pharmaceuticals inc (DPRX) Key Developments

Dipexium Pharmaceuticals, Inc. Presents at 2015 Sidoti Emerging Growth Conference, Sep-02-2015 08:00 AM

Dipexium Pharmaceuticals, Inc. Presents at 2015 Sidoti Emerging Growth Conference, Sep-02-2015 08:00 AM. Venue: Marriott Marquis in Times Square, New York, New York, United States. Speakers: David P. Luci, Co-Founder, Chief Executive Officer, President, Secretary and Director.

Dipexium Pharmaceuticals Surpasses Treatment of 50% of Subjects in Pivotal Phase 3 Clinical Trial

Dipexium Pharmaceuticals, Inc. announced that its OneStep-1 Phase 3 clinical trial has passed the 50% enrollment milestone. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials (180 patients per clinical trial) being conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration and Dipexium for evaluation of Locilex for the treatment of patients with mild infections of diabetic foot ulcers. As of today, 43 clinical trial centers, out of a total of 60 currently open for enrollment across both pivotal Phase 3 clinical studies, OneStep-1 and OneStep-2, have enrolled at least one patient. New clinical trial sites are being added to the program in the coming weeks. The company anticipates completing enrollment and filing a New Drug Application for FDA approval in 2016.

Dipexium Pharmaceuticals Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Dipexium Pharmaceuticals Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $4,034,523 against $3,920,484 a year ago. Net loss was $4,031,908 against $3,920,113 a year ago. Basic and diluted net loss per common share was $0.47 against $0.46 a year ago. The change was primarily due to a $0.4 million increase in professional and administrative costs and stock-based compensation expenses, partially offset by a decrease in research and development expenses of $0.3 million due to the higher manufacturing expenses in 2014 related to the commencement of clinical trials. For the six months, the company reported loss from operations of $8,222,349 against $6,464,323 a year ago. Net loss was $8,219,141 against $6,463,952 a year ago. Basic and diluted net loss per common share was $0.96 against $0.90 a year ago. This change was primarily due to a $2.1 million increase in general and administrative expenses, offset by a $0.4 million decrease in research and development expenses. Net cash used in operating activities was $6.2 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DPRX:US $14.71 USD -0.54

DPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DPRX.
View Industry Companies
 

Industry Analysis

DPRX

Industry Average

Valuation DPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIPEXIUM PHARMACEUTICALS INC, please visit www.dipexiumpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.